- Australia
- /
- Healthtech
- /
- ASX:ALC
Further weakness as Alcidion Group (ASX:ALC) drops 14% this week, taking three-year losses to 40%
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand at stock picking, you risk returning less than the market. We regret to report that long term Alcidion Group Limited (ASX:ALC) shareholders have had that experience, with the share price dropping 40% in three years, versus a market return of about 42%. More recently, the share price has dropped a further 22% in a month. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.
With the stock having lost 14% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
Alcidion Group became profitable within the last five years. That would generally be considered a positive, so we are surprised to see the share price is down. So it's worth looking at other metrics to try to understand the share price move.
With revenue flat over three years, it seems unlikely that the share price is reflecting the top line. We're not entirely sure why the share price is dropped, but it does seem likely investors have become less optimistic about the business.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
We know that Alcidion Group has improved its bottom line lately, but what does the future have in store? This free report showing analyst forecasts should help you form a view on Alcidion Group
A Different Perspective
We're pleased to report that Alcidion Group shareholders have received a total shareholder return of 38% over one year. There's no doubt those recent returns are much better than the TSR loss of 5% per year over five years. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 2 warning signs for Alcidion Group you should be aware of.
For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:ALC
Alcidion Group
Engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom.
Flawless balance sheet with reasonable growth potential.
Market Insights
Community Narratives


